MARS 2 Trial: The Future of Pleurectomy Decortication in Pleural Mesothelioma

MARS 2 Trial: The Future of Pleurectomy Decortication in Pleural Mesothelioma

ByHolly Zink

Malignant pleural mesothelioma, a deadly cancer, often comes from asbestos exposure. It is hard to treat due to its aggressiveness and the challenges of full surgical removal. The MARS 2 trial investigated if extended pleurectomy decortication (P/D) could boost survival and life quality in patients with resectable mesothelioma. A new article looks into the MARS 2 trial’s results, explains clinical trials, and suggests why mesothelioma patients should join them. Understanding Clinical Trials Clinical trials are research studies conducted to evaluate new medical treatments, drugs, or procedures in humans. These trials are essential for advancing medical knowledge and improving patient care. Clinical trials are typically divided into several phases: Phase I: Tests the safety and dosage of a new treatment in…

Mesothelioma Clinical Trials: Insights from the MARS 2 Study

Mesothelioma Clinical Trials: Insights from the MARS 2 Study

ByHolly Zink

Malignant pleural mesothelioma is a rare, aggressive cancer. It affects the chest wall’s lining, linked to asbestos exposure. Each year, over 2,500 in the United Kingdom are diagnosed. The disease has a poor outlook and limited treatments. The MARS 2 study investigated if adding surgery to chemotherapy could enhance survival. A new article delves into challenges in recruiting for RCTs, like MARS 2. It also highlights these trials’ crucial role in medical research and treatment progress. Challenges in Recruiting for RCTs Recruiting for RCTs is tough, especially for studies comparing surgery to non-surgery. The MARS 2 study faced many challenges. Patients with mesothelioma often get mixed advice from different doctors. This made recruiting hard. Also, doctors’ biases influenced their willingness…